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Infection with a high dose of the intracellular parasitic protozoan Leishmania major
induces a sustained hyperalgesia in susceptible BALB/c mice accompanied by up-
regulation of the pro-inflammatory cytokines IL-1β and IL-6. Interleukin-13 (IL-13) has
been shown to reduce this hyperalgesia (despite increased levels of IL-6) and the
levels of IL-1β during and after the treatment period. These findings favor the cytokine
cascade leading to the production of sympathetic amines (involving TNF-α and KC)
over prostaglandins (involving IL-lβ and IL-6) as the final mediators of hyperalgesia. The
aim of this study was to investigate the effect of daily treatment with the β-blockers
atenolol on L. major-induced inflammation in mice with respect to hyperalgesia as well
as the levels of TNF-α and KC (the analog of IL-8 in mice). Our data demonstrates
that atenolol is able to reduce the L. major induced sustained peripheral hyperalgesia,
which does not seem to involve a direct role for neither IL-lβ nor KC. Moreover, our
results show that TNF-α may play a pivotal and direct role in sensitizing the peripheral
nerve endings (nociceptors) since its level was reduced during the period of atenolol
treatment, which correlates well with the reduction of the observed peripheral, but not
central, hyperalgesia. These findings contribute to a better understanding of the cytokine
cascade leading to hyperalgesia and may lead to the development of new and more
efficient medications for many types of pain.
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INTRODUCTION
The course and outcome of cutaneous leishmaniasis caused by the parasite Leishmania major
depends on the type of immune response mounted by the host, whereby the humoral and
the cell-mediated responses are, respectively, associated with the susceptibility and resistance
to the prevailing infection (Cunningham, 2002), because these parasites have the capacity to
escape the humoral response by residing in the phagolysosomes of macrophages. The type of the
immune response itself depends on many factors including the genetic background of the host
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(Sakthianandeswaren et al., 2009), the cytokine milieu (Liu
and Uzonna, 2012), and the dose of the injected parasite.
Regardless of the course and outcome of the infection, the
induced inﬂammatory response involves hyperalgesia, which
is the enhancement of pain sensitivity to noxious stimuli
and spontaneous pain (Driessen, 2007; Cervero, 2009) due to
sensitization of nociceptors (hypernociception). Sensitization
of nociceptors is of two types; peripheral sensitization and
central sensitization. Peripheral sensitization is an increased
responsiveness to stimuli by the peripheral ends of nociceptors.
These neurons transfer signals from peripheral targets (skin,
joints, muscle, and viscera) to the central nervous system
(Spinal cord and brainstem) (Woolf and Ma, 2007). Even
though pain hypersensitivity is mainly based on peripheral
sensitization, high levels of activity lead to the activation
of dorsal horn nociceptors resulting in the modiﬁcation of
sub threshold innocuous stimuli so that they activate second
order neurons in the dorsal horn giving rise to a central
sensation of pain which is so called allodynia (Kidd and Urban,
2001).
Hypernociception is induced by the direct action of the
ﬁnal inﬂammatory mediators—prostaglandins and sympathetic
amines—on peripheral nociceptors. Subsequently, the secondary
signaling pathways [mediated by cyclic AMP (cAMP), protein
kinase A (PKA), and protein kinase C (PKC)] are triggered
lowering the nociceptor threshold and increasing neuronal
membrane excitability (Amaral et al., 2008). Although
prostaglandins and sympathetic amines are suspected to be
the ﬁnal sensitizers of the nociceptors (Saﬁeh-Garabedian
et al., 2002), their production is preceded by the release
of a cascade of cytokines and chemokines (Cunha et al.,
2005). It is widely accepted that tumor factor α (TNF-α),
which is a potent pro-inﬂammatory cytokine and is rapidly
produced in large quantities by macrophages in response to
inﬂammatory stimuli (Verri et al., 2006), can initiate two
independent and parallel pathways. One cascade involves the
release of interleukin 1β (IL-1β) and IL-6 leading to prostanoids
production while the other cascade involves interleukin 8 (IL-8)
(or Keratinocyte-Derived Chemokine/KC in mice), leading to
production of sympathomimetic mediators (Cunha et al., 1992;
Figure 1).
As to cutaneous leishmaniasis, a persistent hyperalgesia was
reported in BALB/c mice infected with high dose (Kanaan
et al., 2000) and a short lived one in those infected with
low dose of the parasite (Karam et al., 2006). While assessing
the eﬀect of thymulin (Kanaan et al., 2000), IL-10 (Karam
et al., 2007), and IL-13 (Karam et al., 2011) on L. major
induced hyperalgesia, it was shown that those substances could
reverse the low pain thresholds during the treatment period.
This eﬀect was accompanied by the reduction of the increased
levels of nerve growth factor (NGF) and IL-1β and by a
further upregulation of IL-6 (Karam et al., 2006). However,
although hyperalgesia was restored after stopping the treatment
with IL-10 and IL-13, the levels of IL-6 remained upregulated
(Karam et al., 2007) and interestingly those of IL-1β (in the
case of IL-13 treatment) remained down-regulated (Karam
et al., 2011) at most time points of the whole experimental
FIGURE 1 | Simplified hyperalgesia pathways in rats. Ag (antigen), IL
(interleukin), TNF-α (Tumor necrosis factor-α), KC (Keratinocyte derived
chemokine) (Verri et al., 2006).
period. By correlating the pain thresholds with the cytokines
levels time courses as well as the treatment period, it was
concluded that IL-1β and IL-6 do not play a direct role and that
other mediators are involved in L. major induced hyperalgesia
at least during later stages of the infection. Taken together,
these results suggest that a more pronounced role can be
attributed to the sympathetic amines as the ﬁnal mediators
of L. major induced hyperalgesia; therefore TNF-α and/or
(KC) should most probably be the intermediate mediators.
Consequently, investigating the role of cyclooxygenase inhibitors
(as indomethacin) as well as beta blockers (as atenolol) should
help in having a better idea about the pathway leading to
L. major induced hyperalgesia inmice. Indomethacin is known to
inhibit the cyclooxygenases 1 and 2 (COX-1/COX2) responsible
for the production of PGE2 resulting in the reduction of
hyperalgesia. The inhibition of hyperalgesia is mediated through
the inhibition of the pro-inﬂammatory cytokine IL- 1β (Cunha
et al., 1991).
Atenolol is known to reduce hyperalgesia to bradykinin,
LPS (Ferreira et al., 1993), kallidin, and DABK (des Arginine
Bradykinin) (Poole et al., 1999). This reduction of hyperalgesia
was suggested to be through direct eﬀect on the levels of IL-
8 (Cunha et al., 1991). Therefore, the aim of this study was to
investigate the eﬀect of daily treatment with Indomethacin and
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the β-blockers atenolol on L. major-induced inﬂammation in
mice with respect to hyperalgesia and levels of IL-lβ, TNF-α and
KC.
MATERIALS AND METHODS
Experimental Animals
Adult female BALB/c mice, provided by the animal house
at the University of Balamand (20–30 g) were used in all
the experiments performed in this study. The animals were
housed under optimal conditions of light and temperature
(12 h light and 12 h dark cycles; 22 ± 3◦C) and received
solid food and water ad libitum. During the period of the
experiments, the mice were kept in groups of ﬁve or six, in
clear plastic cages with solid ﬂoors covered with 3–6 cm of
saw dust. All experimental procedures were carried out with
ethics committee approval from the University of Balamand
and with strict adherence to the ethical guidelines for the
study of experimental pain in conscious animals (Zimmerman,
1983).
Parasite Culture and Preparations
Leishmania major (MHOM/SU/73/5 ASKH) parasites
(purchased from the London School of Hygiene and Tropical
Medicine, London, UK) were grown at 22 ± 1◦C to 25 ± 1◦C
in a standard monophasic medium and sub-cultured weekly.
The medium was made of nutrient broth (Peptic digest of
animal tissue 5 g/L, Sodium chloride 5 g/L, Beef extract
1.500,Yeast extract 1.5 gms/L and ﬁnal pH of 7.4 ± 0.2 at
25◦C) supplemented with 20% fetal bovine serum, 100 IU/ml
of penicillin, and 100 IU/ml of streptomycin (Sigma). The
medium containing the promastigote forms of the parasite
were centrifuged for 15 min at 2500 rpm and the parasites
were resuspended in 1 ml nutrient broth medium. The parasite
count was determined in a Trypan blue solution using a
hemocytometer and readjusted to have 4 × 106 parasites per
50 μl nutrient broth medium for a high dose of L. major. All
mice received intraplantar injection subcutaneously (s.c.) with
the parasite in their left hind paw.
The reported results are based on two sets of experiments each
involving diﬀerent groups of mice (n = 5 in each) which were
used either for the behavioral pain tests or the determination of
the levels of cytokines in the paws of the mice.
Behavioral Measurements
Experimental Groups
Seven groups of mice were subjected to diﬀerent pain tests 3 days
before any treatment, and then ﬁve groups received i.pl. injection
high dose of L.major (4× 106 promastigotes/50μl nutrient broth
medium/left hind paw): one group was left with no treatment,
another one was treated with indomethacin (5 mg/kg) and three
groups were treated with atenolol (0.5, 1.0, 2.0 mg/kg/100 μl,
respectively). All treated groups received daily i.p. injections
for 7 days. The last two groups consisted of naïve (neither
infected nor treated) mice and those injected s.c. in the left paw
TABLE 1 | Experimental groups used in the behavioral tests.
Group Parasitic injections (s.c
4 × 106 parasites)
Treatment (i.p.)
1 None None
2 None Parasites culture medium
3 L. major None
4 L. major 5.0 mg/kg Indomethacin
5 L. major 0.5 mg/kg Atenolol
6 L. major 1.0 mg/kg Atenolol
7 L. major 2.0 mg/kg Atenolol
with the culture medium and both were used also as control
(Table 1).
All groups were subjected to pain tests daily except on
weekends following the injections for a period of 24 days.
Pain Tests
The hot plate (HP) and the tail ﬂick (TF) tests were used to assess
the thermal pain thresholds.
The tail immersion test
The tails of the mice were immersed into a water bath of distilled
water, the temperature of which being adjusted at T = 50◦C
(±0.5◦C). The time interval between the immersion of the
tail and the tail ﬂicking reaction was recorded using a digital
stopwatch with a 1/100 second precision. Each animal was
subjected to this test three times with a three minutes interval
between consecutive measurements and the average was recorded
(Kanaan et al., 1996).
The hot plate test
Each animal was placed on a hotplate analgesia meter (Harvard
Apparatus) with the temperature being adjusted at T = 51◦C
(±0.5◦C). The latency of paw licking or jumping or urinating was
taken.
Immunoassays
Tissue Processing Assay
Four sets of mice, each containing ﬁve groups (n = 5), were used
in this part of the study. Two sets were infected s.c. with L. major
(4 × 106 promastigotes/50 μl nutrient broth medium/left hind
paw) and one of them was treated intraperitoneally (i.p.) with
atenolol (2.0 mg/kg) for 7 days. The other two sets were used as
control (one consists of naive mice and the other of mice infected
with L. major-free broth medium).
The skin of both right (non-infected) and left (infected)
hind paws of mice of the diﬀerent sets was removed under
deep anesthesia with chloroform at days 2, 4, 6, 13, 21 post-
infection.
The paws were individually homogenized (using IKA T 10
basic ULTRA-TURRAX homogenizer) for 1 min at a speed
of 20,000 r.p.m. in 1.2 ml of homogenization buﬀer. The
homogenization buﬀer was prepared by dissolving 139.83 mM
NaCl. 2.68 mM KCl, 1.47 mM KH2PO4, 8.09 mM Na2HPO4
in 100 ml double distilled water [(pH 7.2–7.4). It constituted
of 399.58 mM of NaCl, 0.5 g bovine serum albumin (BSA),
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50 μl of tween 20 and two tablets protease inhibitor to
100 ml of PBS. The homogenized samples were centrifuged at
13000 g for 60 min at 4◦C; supernatants were removed and
stored in pyrogen/endotoxin-free tubes at –82◦C until further
usage.
The supernatants were than assayed for levels of IL-1β, TNF-
α, and KC using a two-site enzyme-linked immunosorbent
assay (ELISA) kits (QIAGEN). For all assays, microtiter
plates (Corning) were setup according to the manufacturer’s
instructions and read at 450 nm using Ascent software (Epoch-
Biotek).
Paw Thickness
In order to make sure that the strain of L. major causes cutaneous
leishmaniasis, the paw thickness of one group of mice that
received i.pl. injection with high dose of the parasite (4 × 106
promastigotes/50 μl nutrient broth medium/left hind paw) was
measured using a digital caliper on a weekly basis for 32 weeks
post-infection.
Data Analysis
Values of pain tests represent the average of three trials at each
time interval and plotted as time latency versus duration of test.
For the immunoassays, the measured levels of each cytokine were
averaged on every tissue removal date for each experimental
group. Comparison among groups was located using a one-
way ANOVA followed by a Bonferoni post hoc test. Results
having p < 0.05, p < 0.01, and p < 0.001 were considered
signiﬁcant.
RESULTS
L. major Infection
Effect of High Dose L. major on the Paw Thickness of
Mice and Pain Thresholds
In order to demonstrate the L. major infection in mice, the paw
thickness of the infected paws with high dose of L. major (4× 106
promastigotes/50 μl nutrient broth medium/left hind paw) was
assessed using a digital caliper.
The subcutaneous injection of a high dose of L. major caused
a signiﬁcant change in the paw thickness of the infected paw of
infected mice starting at week 6 post-infection and continued
to increase throughout the period of the experiment reaching
5.39 ± 0.49 mm at week 30 post-infection for the infected paw as
compared to 2.69± 0.12mm for the non-infected paw (p< 0.001;
Figure 2).
The injection of L. major produced a signiﬁcant decrease
in the HP latency (as calculated with reference to non-infected
mice). It rapidly dropped starting day 2 post-infection from
19.4 ± 0.61 s in non-infected mice to 11.8 ± 0.83 s in the infected
mice (p < 0.001; Figure 3A).
As to the TF latency, the infection with high dose
of L. major caused a signiﬁcant decrease at day 6 post-
infection. It dropped from 6.5 ± 0.25 s to 4.58 ± 0.28 s
(p < 0.001). TF latency showed another signiﬁcance decrease
at day 13 post infection reaching 3.92 ± 0.36s (p < 0.01)
FIGURE 2 | Effect of Leishmania major infection on the paw thickness
in mice infected with high dose (4 × 106 promastigotes/50 μl nutrient
broth medium/left hind paw). Each result is the mean of 5 mice ± SEM and
the degree of significance of the difference was calculated with reference to
the non-infected paw.
FIGURE 3 | The time course of the effect of the daily intraperitoneal
(i.p.) injection of indomethacin on L. major (high dose) induced
hyperalgesia: as assessed by (A) the Hot Plate (HP) Test and (B) the
Tail Flick (TF) Test. Mice were injected with 4 × 106 promastigotes per 50 μl
per left hind paw and another group also with 5.0 mg/kg of indomethacin for 7
consecutive days. Each result is the mean of 5 mice ± SEM and the degree of
significance was calculated with reference to indomethacin non-treated mice.
as compared to non-infected mice 5.8 ± 0.134 s and this
eﬀect was sustained through the whole experimental period
(Figure 3B).
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Treatment with Indomethacin
Pain Thresholds
The infection of mice with high doe of L. major resulted in a
signiﬁcant decrease in the pain thresholds as assessed by the
HP and TF tests. However, treatment with daily injections of
indomethacin (5.0 mg/kg) for 7 consecutive days did not result in
any signiﬁcant diﬀerence in the HP latencies of the mice infected
with high dose L. major and treated compared to those infected
with L. major and not treated with indomethacin at any of the
time points (all p values> 0.05; Figure 3A).
In addition, daily treatment with indomethacin did not aﬀect
the TF latencies as compared to the indomethacin non-treated
group at any time point during the experimental period (p> 0.05;
Figure 3B).
Treatment with Atenolol
Pain Thresholds
Treatment with atenolol (0.5, 1.0, 2.0 mg/kg) for 7 consecutive
days produced a signiﬁcant reduction in the high dose L. major-
induced hyperalgesia during the period of treatment. The HP
latency increased at day 1 post-infection from 11.8 ± 0.83 s in
the mice infected with L. major alone to 14.1 ± 0.41 s in the
group treated with 0.5 mg/kg atenolol (p < 0.01; Figure 4A).
This signiﬁcant diﬀerence in HP latency was also observed in the
group treated with 1.0 mg/kg atenolol (14.5 ± 0.22 s; Figure 4B),
and the group treated with 2.0 mg/kg atenolol (14.8 ± 0.36 s;
Figure 4C). However, the diﬀerence between the HP latencies
of the treated mice and the infected mice became signiﬁcant
especially from day 7 through day 10 when the maximum eﬀect
was reached. Thereafter, the levels started to decrease to reach a
minimum of 13.97 ± 0.75 s (0.5 mg/kg/100 μl), 14.18 ± 0.59 s
(1.0 mg/kg/100 μl), and 14.32 ± 0.83 s (2.0 mg/kg/100 μl)
at day 24 post-infection as compared to 14.76 ± 0.53 s in
the mice infected with high dose of L. major (Figures 4A–C,
respectively) and the diﬀerence between those two groups
became insigniﬁcant.
On the other hand, daily treatment with i.p. atenolol did
not aﬀect the TF latency as compared to the non-treated group
at any time spot during the experimental period (p > 0.05;
Figures 5A–C).
Although the three concentrations of atenolol were eﬃcient
in reducing the L. major induced hyperalgesia, the highest
concentration (2.0/mg/kg) seems to be the most eﬀective one at
most post infection dates. Therefore, this concentration was used
to perform the ELISA assays.
Cytokines
Eﬀect of atenolol (2.0 mg/kg) on the level of TNF-α in mice
infected with high dose of L. major
The subcutaneous injection of a high dose of L. major (4 × 106
promastigotes/50 μl nutrient broth medium/left hind paw)
caused a signiﬁcant increase in the levels of TNF-α, in the infected
(left) and non-infected (right) hind paws at most time points of
the experiment (till day 21 post-infection) (Figures 6A,B).
Atenolol reduced signiﬁcantly the levels of TNF-α in the
infected paws of mice starting day 2 post-infection becoming
FIGURE 4 | The time course of the effect of the daily i.p. injection of
atenolol on L. major (high dose) induced hyperalgesia as assessed by
the HP Test. Mice were injected with 4 × 106 promastigotes per 50 μl per
left hind paw and three groups were also treated with Atenolol 0.5 mg/kg (A),
or 1.0 mg/kg (B), or 2.0 mg/kg (C) for 7 consecutive days. Each result is the
mean of 5 mice ± SEM and the degree of significance was calculated with
reference to atenolol non-treated mice.
more signiﬁcant at day 7 post-infection when the levels of TNF-α
reached 22.79 ± 3.77 pg/hind paw in the paws of treated mice as
compared to 80.98 ± 6.83 pg/hind paw in the infected paws of
non-treated mice (p < 0.001; Figure 6A).
As for the right (non-infected) paws of mice infected with
high dose L. major the eﬀect of atenolol on the levels of
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FIGURE 5 | The time course of the effect of the daily i.p. injection of
Atenolol on L. major (high dose) induced hyperalgesia as assessed by
the TF test. Mice were injected with 4 × 106 promastigotes per 50 μl per left
hind paw and three groups were also treated with Atenolol 0.5 mg/kg (A), or
1.0 mg/kg (B), or 2.0 mg/kg (C) for 7 consecutive days. Each result is the
mean of 5 mice ± SEM and the degree of significance was calculated with
reference to atenolol non-treated mice.
TNF-α was only signiﬁcant at day 4 post infection becoming
28.29 ± 15.27 pg/hind paw as compared to 79.01 ± 7.91
pg/hind paw for the infected atenolol untreated mice (p < 0.01;
Figure 6B).
FIGURE 6 | Effect of the daily i.p. injection of atenolol on the level of
TNF-α in the paws of mice infected with high dose (4 × 106
promastigotes/50 μl nutrient broth medium/left hind paw) of L. major:
(A) left (infected) paws (B) right (non-infected) paws. Mice were injected
with 2.0 mg/kg of atenolol (i.p.) for 7 consecutive days and the levels of TNF-α
were assessed at days 2, 4, 7, 14, and 21 post-infection. Each result is the
mean of 5 mice ± SEM and the degree of significance was calculated with
reference to atenolol non-treated infected mice.
Eﬀect of Atenolol 2.0 mg/kg on the Level of IL-1 in mice
infected with high dose of L. major
The subcutaneous injection of a high dose of L. major (4 × 106
promastigotes/50 μl nutrient broth medium/left hind paw)
caused a signiﬁcant change in the levels of IL-1 in the infected
paws of mice starting day 2 post-infection when it increased from
2.75 ± 0.67 pg/hind paw in the non-infected mice to 146 ± 7.32
pg/hind paw (p < 0.001). This signiﬁcant increase was sustained
till day 7 post-infection (Figure 7A). On the other hand, the levels
of IL-1β in the non-infected paw (right) showed no signiﬁcant
change at any time point when compared to the control mice
(Figure 7B).
Daily treatment with atenolol (2.0 mg/kg) for 7 days had
no signiﬁcant eﬀect, at any date post-infection, on the level of
IL-1β neither in the infected paws nor in the non-infected paws
of mice infected with L. major as compared to those infected
with L. major but not treated with atenolol (all p values > 0.05)
(Figures 7B).
Eﬀect of Atenolol (2.0 mg/kg) on the level of KC in mice
infected with high dose of L. major
The subcutaneous injection of a high dose of L. major (4 × 106
promastigotes/50 μl nutrient broth medium/left hind paw)
caused a signiﬁcant increase in the level of KC at day 2 post-
infection in the infected hind paw of themice (104± 2.28 pg/hind
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FIGURE 7 | Effect of the daily i.p. injection of atenolol on the level of
IL-lβ in the paws of mice infected with high dose (4 × 106
promastigotes/50 μl nutrient broth medium/left hind paw) of L. major:
(A) left (infected) paws (B) right (non-infected) paws. Mice were injected
with 2.0 mg/kg of atenolol (i.p.) for 7 consecutive days (and the levels of IL-lβ
were assessed at days 2, 4, 7, 14, and 21 post-infection. Each result is the
mean of 5 mice ± SEM and the degree of significance was calculated with
reference to atenolol non-treated mice.
paw) (p < 0.001) as compared to the level in the control group
(5.83± 0.124 pg/hind paw). A signiﬁcant increase was also shown
at day 7 when the KC levels became 23.33 ± 9.18 in the infected
paws of infected mice. The levels of KC at day 14 and 21 were not
detectable (Figure 8).
Treatment with daily injections of atenolol (2.0 mg/kg) for
7 days resulted in no signiﬁcant diﬀerence at day 2 and 4 post
infection between the levels of KC in the paws of mice infected
with L. major and those infected with the parasite and treated
with atenolol (p > 0.05 ). The level of KC at day 7 showed a
decrease in the paws of mice infected and treated (8.948 ± 0.63
pg/hind paw) as compared to the infected and non-treated mice
(23.33 ± 9.18 pg/hind paw), the p-value was <0.01 (Figure 8).
As for the level of KC in the right (non-infected) paws, it was
not detected at all time points of the experiment.
DISCUSSION
It is generally well accepted that the inﬂammatory
hypernociception, in many animal models, depends on two
hyperalgesic pathways involving the sympathetic amines and/or
FIGURE 8 | Effect of the daily i.p. injection of atenolol on the level of
KC in the paws of mice infected with high dose
(4 × 106promastigotes/50 μl nutrient broth medium/left hind paw) of
L. major: paws removed from the left paws of mice. Mice were injected
with 2.0 mg/kg of atenolol (i.p.) for 7 consecutive days and the levels of KC
were assessed at days 2, 4, 7, 14, and 21 post-infection (at day 14 and 21
the level of KC in the group infected is not detected). Each result is the mean
of 5 mice ± SEM and the degree of significance was calculated with reference
to atenolol non-treated mice.
prostanoids as ﬁnal mediators. In the cutaneous leishmaniasis
model, the subcutaneous injection of high dose of L. major
in the paws of BALB/c mice causes a sustained hyperalgesia
accompanied by an increase in the levels of pro-inﬂammatory
cytokines IL-lβ and NGF (Kanaan et al., 2000) while infection
with a low dose of the parasite causes a short lived hyperalgesia
accompanied by the upregulation of IL-1β and IL-6 (Karam et al.,
2006).
However, while assessing the eﬀect of IL-10 and IL-13 on
L. major induced hyperalgesia in BALB/cmice, it has been shown
that IL-lβ and IL-6 do not play a direct role in evoking or
sustaining the low pain thresholds (Karam et al., 2011) suggesting
that this hyperalgesia is mainly mediated by the pathway leading
to the production of sympathetic amines.
Therefore, we started by re-evaluating the eﬀect of L. major
infection on the pain thresholds of BALB/c mice. In line with
previous studies (Kanaan et al., 2000; Karam et al., 2007), we
demonstrated that the subcutaneous injection of a high dose
of L. major causes a sustained hyperalgesia as measured by the
signiﬁcant decrease in the pain thresholds toward the HP test. In
addition to peripheral sensitization, we have shown that L. major
infection results in decreased latency in TF test starting day 12
post-infection, suggesting a central sensitization phenomenon
(Mahesh et al., 2010).
In order to conﬁrm or reject any direct role of the prostanoid
pathway in the L. major induced hyperalgesia, mice were treated
with indomethacin, which is a cyclooxygenase inhibitor. Our
results showed that indomethacin caused no signiﬁcant eﬀect
on L. major induced low pain thresholds providing a further
proof that this hyperalgesia model is mainly dependent on the
sympathetic amines pathway.
Accordingly, we assessed the eﬀect of atenolol, a β-blocker
and β1-adrenoceptor antagonist on the L. major induced
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pain thresholds; Atenolol is known to limit hyperalgesia in
several models other than leishmaniasis through blocking the
sympathetic amines. The i.p. injection of atenolol induced a
dose-dependent (0.5, 1.0, 2.0 mg/kg) reduction in the peripheral
hyperalgesia, as assessed by the HP test, during the period of
treatment. However, atenolol did not have any signiﬁcant eﬀects
on the central sensitization as assessed by the TF test.
The above results were encouraging to investigate the eﬀect
of atenolol on the levels of some key cytokines that might be
involved in the process of hyperalgesia. Therefore, we assessed
the levels of TNF-α, IL-lβ and KC in the paws of L. major
infected mice treated with 60 mg/100 μl/mouse for 7 consecutive
days.
There have been correlations between tissue levels of TNF-
α and pain and hyperalgesia in a number of painful diseases
(Barnes et al., 1992; Shafer et al., 1994; Tak et al., 1997; Lindenlaub
and Sommer, 2003). In addition there is accumulating evidence
that TNF-α, which is released by activated glial cells, is an
important mediator of pain and hyperalgesia in the central
nervous system (Watkins et al., 2007). Upon L. major infection,
no signiﬁcant change has been detected in the levels of TNF-
α in infected BALB/c mice (Kanaan et al., 2000). In contrast
to previous studies, our results showed that following infection
with L. major and using the same mouse strain, the levels of
TNF-α increased at all time points of the experiment at both
the local infected site and the distal non-infected site, suggesting
a major role of TNF-α in the observed peripheral and central
sensitization.
Our results showed that atenolol is able to reduce the levels
of TNF-α in the infected paws of the mice throughout the
treatment period. Thereafter, the levels of TNF-α started to
increase reaching values very close to levels of this cytokine in the
paws of mice infected with high dose of L. major but not treated
with atenolol. This time course of the levels of TNF-α correlates
very well with that of the observed peripheral hyperalgesia as
assessed by the HP test. As to the levels in the non-infected paws,
atenolol seems to have a reducing eﬀect trend on the TNF-α
levels starting day 4 post-infection and throughout the whole
experimental period (even when the treatment was stopped);
however, atenolol treatment did not reduce the TF low pain
thresholds suggesting that this beta blocker can, most probably
by down-regulating the TNF-α levels, reduce the peripheral but
not the central hyperalgesia.
Although several studies reported that L. major induced
hyperalgesia is mediated through cytokines, in particular a
sustained up-regulation of IL-lβ (Saade et al., 2000; Karam et al.,
2007), Karam et al. (2011) have shown that IL-lβ has no direct
role in L. major induced hyperalgesia using the same dose of
parasites and same mouse strain. Our results are in agreement
with the latter study since L. major infection caused a sustained
peripheral hyperalgesia while the levels of IL-lβ were signiﬁcantly
increased just during the ﬁrst few days of infection. Moreover,
and as expected, atenolol treatment did not have any signiﬁcant
eﬀect on the levels of IL-lβ which remained up-regulated while
the peripheral hyperalgesia was reduced during the period of
treatment. These results suggest that mediators other than IL-lβ
are involved in L. major induced peripheral hyperalgesia.
From the other side, the tendency of the levels of IL-lβ
to increase in the non-infected paws of the mice due to
L. major infection, and the inability of atenolol to signiﬁcantly
reduce them parallel to the low TF threshold values, might
suggest a possible role of this pro-inﬂammatory cytokine in
the observed central sensitization. However, since indomethacin
did not reverse those low TF threshold values, and taking
into consideration that hyperalgesia evoked by IL-lβ was not
attenuated by atenolol (Cunha et al., 1991), and that, in mice,
IL-lβ produces hypernociception through the induction of PGE2
(Cunha et al., 2005), the latter hypothesis is not favored except
if IL-lβ is mediating hyperalgesia via mediators other than
prostanoids.
Therefore, more studies are required to investigate the serial
levels of pro-inﬂammatory cytokines occurring at the level of the
brain and spinal cord.
Previous studies indicated that in response to L. major, KC
mRNA was rapidly and transiently induced in the infected skin
(Muller et al., 2001) and that IL-8/CXCL8 (human homologue
of KC) or CINC-1/CXCL (rat homolog of KC) induced
mechanical hypernociception is inhibited by β–adrenergic
receptor antagonists, but not by COX inhibitors (Cunha et al.,
1991). However, no studies have been done previously about the
levels of KC in the L. major evoked hyperalgesia. In this study,
the levels of KC increased signiﬁcantly in the infected paws of
mice at days 2 and 7 post-infection as compared to control levels.
However, atenolol did not result in any signiﬁcant change in the
levels of this cytokine during the period of treatment (except
at day 7 post-infection) while the peripheral hyperalgesia was
reduced. These results suggest that although KC might play a
role in provoking L. major induced peripheral hyperalgesia, it
doesn’t contribute neither to sustained hyperalgeisa nor to the
atenolol reversal of the low pain thresholds. Furthermore, KC
seems to play no role in the central hypernociception since it was
not detected in the non-infected paws of mice while the tails ﬂicks
threshold values were signiﬁcantly low.
CONCLUSION
Our results provide many new insights about the basic
mechanisms involved in the L. major induced hyperalgesia.
We demonstrate here that atenolol reduces peripheral
hyperalgesia but has no signiﬁcant eﬀect on central hyperalgesia.
This eﬀect seems to be mediated by the reduction of the TNF-
α levels in the infected paws of mice. On the other hand,
atenolol did not aﬀect the levels of IL-lβ giving further evidence
that this cytokine does not play a direct role in peripheral or
central hyperalgesia, which is in accordance with previous studies
performed by our group (Karam et al., 2011). Furthermore, our
results demonstrate that atenolol has no eﬀect on the levels
of KC, which seems to play no major role neither in the
sustained peripheral hyperalgesia nor in the central one. Taken
together, and in addition to the observation that indomethacin
does not aﬀect the low pain thresholds in L. major infected
mice, these results provide further evidence that the sympathetic
amines play a more pronounced role in this sustained cutaneous
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leishmaniasis hyperalgesiamodel involving amediator other than
KC. Therefore, TNF-α seems to either directly hypersensitize
the nociceptors or induces the sympathetic amines which can
similarly aﬀect those terminal nerve endings making of the beta
blockers a potential eﬃcient treatment for L. major induced
peripheral hyperalgesia.
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